Sudarma Bogahawaththa

Dr. Sudarma Bogahawaththa

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SBSudarma Bogahawaththa
Sudarma Bogahawaththa
MHMegumi Hara
Megumi Hara
TFTakuma Furukawa
Takuma Furukawa
CIChiharu Iwasaka
Chiharu Iwasaka
TSTakeshi Sawada
Takeshi Sawada
AMAkiko Matsumoto
Akiko Matsumoto
We previously reported a reduced humoral immune response to the COVID-19 vaccines. Subsequently, we observed a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant through a web-based retrospective survey. Based on these findings, we hypothesized that rs671 variant was beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we assessed cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline after one to three doses, whereas subcohort 2 (19 participants) had two observations before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model (183 observations from 45 participants), including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. Our sequential observational studies suggest a beneficial effect of the rs671 variant in SARS-CoV-2 infection via enhanced cellular immune response, providing a potential basis for optimizing preventive measures and drug development.

1 January 2026 in Environmental Health and Preventive Medicine
Verified
Journal Article
Open access
GYGoki Yamada
Goki Yamada
SBSudarma Bogahawaththa
Sudarma Bogahawaththa
YNYuichiro Nishida
Yuichiro Nishida
MHMikako Horita
Mikako Horita
KKKazuhiro Kawamoto
Kazuhiro Kawamoto
AMAkiko Matsumoto
Akiko Matsumoto
The d-ROMs and BAP serum tests are promising markers of oxidative balance in research settings. Conventional assay systems require 30 µL of serum and approximately 10 minutes to analyze a single sample. Although these systems have the advantages of calibration-free operation and the flexibility to perform individual tests at any time, their limited throughput and relatively high cost restrict their use in large-scale studies. To address this issue, we developed a small-scale, semi-automated measurement system incorporating a pipetting robot and a 384-well plate. The system requires only 5.0 µL of serum sample and can process up to 144 samples simultaneously for both d-ROMs and BAP assays (a total of 288 measurements). Based on nonlinearity testing, 450 nm was selected as the optimal wavelength. To maintain linearity across various sample types, including turbid serum, d-ROMs required incubation at 4 °C for one week, and BAP required centrifugation to remove precipitates. Intra- and inter-assay, as well as inter-day, coefficients of variation ranged from 1% to 9% for d-ROMs and 2% to 17% for BAP. Inter-operator variations were <9%. Lipemic serum showed abnormally low BAP values using the conventional method but normal values using our method. In non-turbid samples, the current and conventional methods showed high agreement. Deming regression analysis of log10-transformed d-ROMs values yielded a slope of 1.06 (95% confidence interval between 0.99-1.13), and an intercept of -0.12 (-0.28 to 0.04). The same analysis for BAP yielded a slope of 0.97 (0.821-1.13) and an intercept of -0.12 (-0.391 to 0.625). Stability testing indicated that serum should be stored at -80 °C in volumes ≥100 µL for standard 1.5 mL tubes or ≥21 µL for 96-well format tubes. Our method reduced serum requirements by 83%, reagent use by 93% for d-ROMs and 86% for BAP. Although colorimetric measurement is required after one week of incubation, actual labor time was reduced by approximately 80%. We have developed a high-throughput, cost-effective in-house assay system for large-scale studies. This system provides accurate measurements of oxidative stress markers even in turbid samples, facilitating robust evidence-based research on oxidative stress and health.

20 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SBSudarma Bogahawaththa
Sudarma Bogahawaththa
MHMegumi Hara
Megumi Hara
TFTakuma Furukawa
Takuma Furukawa
CIChiharu Iwasaka
Chiharu Iwasaka
TSTakeshi Sawada
Takeshi Sawada
AMAkiko Matsumoto
Akiko Matsumoto
Because we observed a reduced humoral immune response to the COVID-19 vaccine and subsequently discovered a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant, we hypothesized that rs671 is beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we evaluated cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline and after one to three doses, whereas subcohort 2 (19 participants) had two observations, before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant, but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model, including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. There is lower humoral and higher cellular immunity against SARS-CoV-2 in rs671 variant carriers compared to non-carriers, providing a potential basis for optimizing preventive measures and drug discovery.